(Reuters) - Amgen Inc said its drug met the main goal of improving overall survival in metastatic colorectal cancer patients who have not responded to chemotherapy.
The late-stage study was testing the drug, Vectibix (panitumumab), in combination with best supportive care (BSC), compared with BSC alone.
Patients who received 6 mg/kg of the drug every 14 days and BSC showed an improvement in survival rate, compared with BSC alone, the company said on Thursday.
Vectibix is the first fully human anti-EGFR antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer.
Vectibix was approved in the U.S. in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing metastatic colorectal cancer after disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. In May 2014, the FDA approved Vectibix for use in combination with FOLFOX, as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer.
Colorectal cancer affects about 1.2 million people worldwide each year, Amgen said.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου